Literature DB >> 16775375

Role of immune cells in animal models for inherited peripheral neuropathies.

Chi Wang Ip1, Antje Kroner, Stefan Fischer, Martin Berghoff, Igor Kobsar, Mathias Mäurer, Rudolf Martini.   

Abstract

Mice expressing half of the normal dose of protein zero (P0+/- mice) or completely deficient gap-junction protein connexin 32 -/- mice mimic demyelinating forms of inherited neuropathies, such as Charcot-Marie-Tooth (CMT) neuropathies type 1B and CMT type 1X, respectively. In both models, an almost normal myelin formation is observed during the first months of life, followed by a slowly progressing demyelinating neuropathy. In both models, there is a substantial increase of CD8+ T-lymphocytes and macrophages within the demyelinating nerves. Recently, this has also been observed in mice mildly overexpressing human peripheral myelin protein 22 kD mimicking the most common form of CMT, CMT type 1A. In all demyelinating models, the macrophages show close contacts with intact myelin sheaths or demyelinated axons, suggesting an active role of these cells in myelin degeneration. Additionally, fibroblast-like cells contact macrophages, suggesting a functional role of fibroblast-like cells in macrophage activation. By cross-breeding P0+/- and gap-junction protein connexin 32-/- mice with immunodeficient recombination activating gene-1-deficient mutants, a substantial alleviation of the demyelinating phenotype was observed. Similarly, cross-breeding of P0+/- mice with mutants with a defect in macrophage activation led to an alleviated phenotype as well. These findings demonstrate that the immune system is involved in the pathogenesis of demyelinating neuropathies. In contrast, in P0-/- mice, which display a compromised myelin compaction and axonal loss from onset, immune cells appear to have a neuroprotective effect because cross-breeding with recombination activating gene-1 mutants leads to an aggravation of axonopathic changes. In the present review, we discuss the influence of the immune system on inherited de- and dysmyelination regarding disease mechanisms and possible clinical implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16775375     DOI: 10.1385/nmm:8:1-2:175

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  69 in total

Review 1.  Alzheimer's associated inflammation, potential drug targets and future therapies.

Authors:  G Stuchbury; G Münch
Journal:  J Neural Transm (Vienna)       Date:  2004-07-28       Impact factor: 3.575

Review 2.  Neurovascular mechanisms of Alzheimer's neurodegeneration.

Authors:  Berislav V Zlokovic
Journal:  Trends Neurosci       Date:  2005-04       Impact factor: 13.837

3.  Macrophage-related demyelination in peripheral nerves of mice deficient in the gap junction protein connexin 32.

Authors:  Igor Kobsar; Mathias Mäurer; Thomas Ott; Rudolf Martini
Journal:  Neurosci Lett       Date:  2002-03-01       Impact factor: 3.046

4.  Bone marrow transfer from wild-type mice reverts the beneficial effect of genetically mediated immune deficiency in myelin mutants.

Authors:  M Mäurer; C D Schmid; F Bootz; J Zielasek; K V Toyka; S Oehen; R Martini
Journal:  Mol Cell Neurosci       Date:  2001-06       Impact factor: 4.314

5.  Mechanism of demyelination in experimental allergic neuritis. Electron microscopic studies.

Authors:  P W Lampert
Journal:  Lab Invest       Date:  1969-02       Impact factor: 5.662

Review 6.  Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease.

Authors:  P Young; U Suter
Journal:  Brain Res Brain Res Rev       Date:  2001-10

7.  Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion.

Authors:  E Hauben; O Butovsky; U Nevo; E Yoles; G Moalem; E Agranov; F Mor; R Leibowitz-Amit; E Pevsner; S Akselrod; M Neeman; I R Cohen; M Schwartz
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  Cellular localization of nerve growth factor synthesis by in situ hybridization.

Authors:  C E Bandtlow; R Heumann; M E Schwab; H Thoenen
Journal:  EMBO J       Date:  1987-04       Impact factor: 11.598

10.  Krox-20 controls myelination in the peripheral nervous system.

Authors:  P Topilko; S Schneider-Maunoury; G Levi; A Baron-Van Evercooren; A B Chennoufi; T Seitanidou; C Babinet; P Charnay
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

View more
  14 in total

1.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

2.  Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1X.

Authors:  Janos Groh; Joachim Weis; Hanna Zieger; E Richard Stanley; Heike Heuer; Rudolf Martini
Journal:  Brain       Date:  2011-11-16       Impact factor: 13.501

3.  Charcot–Marie–Tooth disease type 2J with MPZ Thr124Met mutation: clinico-electrophysiological and MRI study of a family.

Authors:  Elena Gallardo; Antonio García; César Ramón; Elías Maraví; Jon Infante; Itziar Gastón; Ángel Alonso; Onofre Combarros; Peter De Jonghe; José Berciano
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

4.  Genetically determined neuropathy (CMT 1A) accompanied by immune dysfunction: a case report.

Authors:  Zsuzsanna Pál; E Kiss; A Gál; T Csépány; A Lengyel; Maria Judit Molnar
Journal:  Inflamm Res       Date:  2009-03-10       Impact factor: 4.575

5.  MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A neuropathy.

Authors:  Bianca Kohl; Stefan Fischer; Janos Groh; Carsten Wessig; Rudolf Martini
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

6.  Intermittent fasting alleviates the neuropathic phenotype in a mouse model of Charcot-Marie-Tooth disease.

Authors:  Irina Madorsky; Katherine Opalach; Amanda Waber; Jonathan D Verrier; Chelsea Solmo; Thomas Foster; William A Dunn; Lucia Notterpek
Journal:  Neurobiol Dis       Date:  2009-04       Impact factor: 5.996

7.  Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy.

Authors:  Alexia Kagiava; Irene Sargiannidou; George Theophilidis; Christos Karaiskos; Jan Richter; Stavros Bashiardes; Natasa Schiza; Marianna Nearchou; Christina Christodoulou; Steven S Scherer; Kleopas A Kleopa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

8.  Ectopic T-cell specificity and absence of perforin and granzyme B alleviate neural damage in oligodendrocyte mutant mice.

Authors:  Antje Kroner; Chi Wang Ip; Johannes Thalhammer; Klaus-Armin Nave; Rudolf Martini
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

9.  Inherited neuropathies.

Authors:  Angelo Schenone; Lucilla Nobbio; Margherita Monti Bragadin; Giulia Ursino; Marina Grandis
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

10.  PD-1 regulates neural damage in oligodendroglia-induced inflammation.

Authors:  Antje Kroner; Nicholas Schwab; Chi Wang Ip; Christoph Leder; Klaus-Armin Nave; Mathias Mäurer; Heinz Wiendl; Rudolf Martini
Journal:  PLoS One       Date:  2009-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.